• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 11:42:06 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care
    Get the next $GWPH alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    GW Pharmaceuticals PLC


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G4210C104


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G4210C104

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 33,084,159
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 33,084,159
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    33,084,159 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    GW Pharmaceuticals PLC
    (b) Address of Issuer's Principal Executive Offices
    Sovereign House, Vision Park, Chivers Way, Cambridge, CA CB24 9BZ, United Kingdom
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G4210C104
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    33,084,159 **
    (b) Percent of Class:
    8.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 33,084,159
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 33,084,159
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 33,084,159 shares or 8.8% of the 374,180,696 shares believed to be outstanding.

    Shares reported include 2,757,013 Depository Receipts, which represent 33,084,159 Common Stock.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    American Funds Fundamental Investors
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Michael J. Triessl
    Date: February 16, 2021
    Name: Michael J. Triessl
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $GWPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GWPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GWPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

      DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl

      5/5/21 9:15:00 AM ET
      $JAZZ
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation

      LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the

      4/28/21 8:00:00 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on GW Pharmaceuticals

      Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold

      2/22/21 7:29:26 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • GW Pharmaceuticals downgraded by Citigroup

      Citigroup downgraded GW Pharmaceuticals from Buy to Neutral

      2/4/21 11:27:13 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • GW Pharmaceuticals downgraded by HC Wainwright

      HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral

      2/4/21 7:30:03 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      3/10/21 11:42:46 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      2/16/21 3:58:07 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      2/16/21 11:42:06 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $GWPH
    Financials

    Live finance-specific insights

    See more
    • How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry

      LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR

      12/3/20 9:00:00 AM ET
      $TAP
      $MO
      $JNJ
      $HEXO
      Beverages (Production/Distribution)
      Consumer Staples
      Medicinal Chemicals and Botanical Products
      Health Care

    $GWPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:25:12 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:21:57 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by GRYSKA DAVID W

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:19:12 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    SEC Filings

    See more
    • SEC Form 15-12B filed by GW Pharmaceuticals Plc

      15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/17/21 6:09:29 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by GW Pharmaceuticals Plc

      S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/5/21 5:27:52 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by GW Pharmaceuticals Plc

      S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/5/21 5:26:02 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care